NR3C2 and prostate cancer: Exploiting these differences can help design antimicrobial agents that specifically inhibit MCR in M. tuberculosis without affecting human AMACR (a drug target for prostate cancer [1,2,4,5,6,7,8]), minimizing potential side-effects.